Immunohistochemical expression of stem cell, endothelial cell, and chemosensitivity markers in primary glioma spheroids cultured in serum-containing and serum-free medium

Neurosurgery

Volumn 66, Issue 5, 2010, Pages 933-947

  Christensen, Karina ^a   Aaberg Jessen, Charlotte ^a   Andersen, Claus ^a   Goplen, Dorota ^b   Bjerkvig, Rolf ^b,c   Kristensen, Bjarne Winther ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF BERGEN   (Norway)

^c LUXEMBOURG INSTITUTE OF HEALTH   (Luxembourg)

Author keywords

Brain tumor stem cell; CD133; Glioma; Immunohistochemistry; Niche; Spheroids

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; BIOLOGICAL MARKER; BMI1 PROTEIN; CD133 ANTIGEN; CD31 ANTIGEN; CD34 ANTIGEN; CD56 ANTIGEN; EPIDERMAL GROWTH FACTOR; GLIAL FIBRILLARY ACIDIC PROTEIN; GLYCOPROTEIN P; KI 67 ANTIGEN; NERVE CELL ADHESION MOLECULE; NESTIN; PARAFFIN; PODOPLANIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSCRIPTION FACTOR SOX2; VON WILLEBRAND FACTOR;

ADULT; AGED; ARTICLE; ASTROCYTOMA; BLOOD VESSEL; CELL CULTURE; CHEMOSENSITIVITY; CLINICAL ARTICLE; CONTROLLED STUDY; CULTURE MEDIUM; ENDOTHELIUM CELL; FEMALE; GLIOBLASTOMA; GLIOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PHENOTYPE; PRIORITY JOURNAL; SCORING SYSTEM; SPHEROID CELL; STEM CELL;

ADULT; AGED; BRAIN NEOPLASMS; CELL CULTURE TECHNIQUES; CULTURE MEDIA; CULTURE MEDIA, SERUM-FREE; ENDOTHELIAL CELLS; EPIDERMAL GROWTH FACTOR; FEMALE; FIBROBLAST GROWTH FACTOR 2; GLIOMA; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PHENOTYPE; SPHEROIDS, CELLULAR; STEM CELLS; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 77951689749     PISSN: 0148396X     EISSN: None     Source Type: Journal    
DOI: 10.1227/01.NEU.0000368393.45935.46     Document Type: Article

References (84)

1. Ignatova TN, Kukekov VG, Laywell ED, Suslov ON, Vrionis FD, Steindler DA. Human cortical glial tumors contain neural stem-like cells expressing astroglial and neuronal markers in vitro. Glia. 2002;39(3):193-206.
2. Singh SK, Clarke ID, Terasaki M, et al. Identification of a cancer stem cell in human brain tumors. Cancer Res. 2003;63(18):5821-5828. (Pubitemid 37187480)
3. Galli R, Binda E, Orfanelli U, et al. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res. 2004;64(19):7011-7021. (Pubitemid 39331011)
4. Kang SK, Park JB, Cha SH. Multipotent, dedifferentiated cancer stem-like cells from brain gliomas. Stem Cells Dev. 2006;15(3):423-435.
5. Lee J, Kotliarova S, Kotliarov Y, et al. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell. 2006;9(5):391-403. (Pubitemid 43668737)
6. Hemmati HD, Nakano I, Lazareff JA, et al. Cancerous stem cells can arise from pediatric brain tumors. Proc Natl Acad Sci USA. 2003;100(25):15178-15183. (Pubitemid 37518036)
7. Bao S, Wu Q, McLendon RE, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006;444(7120):756-760. (Pubitemid 44949604)
8. Bjerkvig R, Tønnesen A, Laerum OD, Backlund EO. Multicellular tumor spheroids from human gliomas maintained in organ culture. J Neurosurg. 1990;72(3):463-475. (Pubitemid 20072971)
9. De Witt Hamer PC, Jonker A, Leenstra S, Ruijter JM, Van Noorden CJ. Quanti -fication of viability in organotypic multicellular spheroids of human malignant glioma using lactate dehydrogenase activity: a rapid and reliable automated assay. J Histochem Cytochem. 2005;53(1):23-34. (Pubitemid 40130117)
10. Kaaijk P, Troost D, Sminia P, et al. Hypofractionated radiation induces a decrease in cell proliferation but no histological damage to organotypic multicellular spheroids of human glioblastomas. Eur J Cancer. 1997;33(4):645-651. (Pubitemid 27223752)
11. Sminia P, Acker H, Eikesdal HP, et al. Oxygenation and response to irradiation of organotypic multicellular spheroids of human glioma. Anticancer Res. 2003; 23(2B):1461-1466. (Pubitemid 36754115)
12. Fehlauer F, Muench M, Rades D, et al. Effects of irradiation and cisplatin on human glioma spheroids: inhibition of cell proliferation and cell migration. J Cancer Res Clin Oncol. 2005;131(11):723-732. (Pubitemid 41577949)
13. Fehlauer F, Muench M, Smid EJ, et al. Combined modality therapy of gemcitabine and irradiation on human glioma spheroids derived from cell lines and biopsy tissue. Oncol Rep. 2006;15(1):97-105.
14. Singh SK, Hawkins C, Clarke ID, et al. Identification of human brain tumour initiating cells. Nature. 2004;432(7015):396-401. (Pubitemid 39551674)
15. Beier D, Hau P, Proescholdt M, et al. CD133+ and CD133- glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res. 2007;67(9):4010-4015. (Pubitemid 46815044)
16. Wang J, Sakariassen P, Tsinkalovsky O, et al. CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells. Int J Cancer. 2008; 122(4):761-768.
17. Zeppernick F, Ahmadi R, Campos B, et al. Stem cell marker CD133 affects clinical outcome in glioma patients. Clin Cancer Res. 2008;14(1):123-129. (Pubitemid 351377986)
18. Breiteneder-Geleff S, Soleiman A, Kowalski H, et al. Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries: podoplanin as a specific marker for lymphatic endothelium. Am J Pathol. 1999;154(2):385-394. (Pubitemid 29094089)
19. Sulman EP, Goodman LD, Le TT, et al. A novel marker of glioma stem cells that is prognostic for treatment response and patient outcome. Proceedings of the 99th Annual Meeting of the American Association for Cancer Research. 2008. Abstract no. 3777.
20. Schmitz M, Temme A, Senner V, et al. Identification of SOX2 as a novel gliomaassociated antigen and potential target for T cell-based immunotherapy. Br J Cancer. 2007;96(8):1293-1301. (Pubitemid 46625072)
21. Vonlanthen S, Heighway J, Altermatt HJ, et al. The bmi-1 oncoprotein is differentially expressed in non-small cell lung cancer and correlates with INK4A-ARF locus expression. Br J Cancer. 2001;84(10):1372-1376. (Pubitemid 32522106)
22. Glinsky GV, Berezovska O, Glinskii AB. Microarray analysis identifies a deathfrom-cancer signature predicting therapy failure in patients with multiple types of cancer. J Clin Invest. 2005;115(6):1503-1521. (Pubitemid 40814659)
23. Hockfield S, McKay RD. Identification of major cell classes in the developing mammalian nervous system. J Neurosci. 1985;5(12):3310-3328. (Pubitemid 16182611)
24. Johansson CB, Momma S, Clarke DL, Risling M, Lendahl U, Frisén J. Identification of a neural stem cell in the adult mammalian central nervous system. Cell. 1999; 96(1):25-34. (Pubitemid 29044150)
25. Strojnik T, Røsland GV, Sakariassen PO, Kavalar R, Lah T. Neural stem cell markers, nestin and musashi proteins, in the progression of human glioma: correlation of nestin with prognosis of patient survival. Surg Neurol. 2007;68(2):133-144. (Pubitemid 47087905)
26. Calabrese C, Poppleton H, Kocak M, et al. A perivascular niche for brain tumor stem cells. Cancer Cell. 2007;11(1):69-82. (Pubitemid 46054518)
27. Bao S, Wu Q, Sathornsumetee S, et al. Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res. 2006;66(16):7843-7848. (Pubitemid 44299144)
28. Borovski T, Verhoeff JJ, Ten CR, et al. Tumor microvasculature supports proliferation and expansion of glioma-propagating cells. Int J Cancer. 2009;125(5):1222-1230.
29. Christensen K, Schrøder HD, Kristensen BW. CD133 identifies perivascular niches in grade II-IV astrocytomas. J Neurooncol. 2008;90(2):157-170.
30. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer. 2005;5(4):275-284. (Pubitemid 40488633)
31. Aaberg-Jessen C, Christensen K, Offenberg H, et al. Low expression of tissue inhibitor of metalloproteinases-1 (TIMP-1) in glioblastoma predicts longer patient survival. J Neurooncol. 2009;95(1):117-128.
32. Wu ZS, Wu Q, Yang JH, et al. Prognostic significance of MMP-9 and TIMP-1 serum and tissue expression in breast cancer. Int J Cancer. 2008;122(9):2050- 2056. (Pubitemid 351441195)
33. Kuvaja P, Würtz SØ, Talvensaari-Mattila A, Brünner N, Pääkkö P, Turpeenniemi-Hujanen,T. High serum TIMP-1 correlates with poor prognosis in breast carcinoma-a validation study. Cancer Biomark. 2007;3(6):293-300. (Pubitemid 351459337)
34. Holten-Andersen M, Christensen IJ, Nilbert M, et al. Association between preoperative plasma levels of tissue inhibitor of metalloproteinases 1 and rectal cancer patient survival. A validation study. Eur J Cancer. 2004;40(1):64-72. (Pubitemid 37542319)
35. Joo YE, Seo KS, Kim HS, Rew JS, Park CS, Kim SJ. Expression of tissue inhibitors of metalloproteinases (TIMPs) in gastric cancer. Dig Dis Sci. 2000;45(1):114-121.
36. Yoshikawa T, Tsuburaya A, Kobayashi O, Sairenji M, Miyagi Y. Protein levels of tissue inhibitor of metalloproteinase-1 in tumor extracts as a marker for prognosis and recurrence in patients with gastric cancer. Gastric Cancer. 2006;9(2):106-113. (Pubitemid 43885768)
37. Rauvala M, Puistola U, Turpeenniemi-Hujanen T. Gelatinases and their tissue inhibitors in ovarian tumors; TIMP-1 is a predictive as well as a prognostic factor. Gynecol Oncol. 2005;99(3):656-663. (Pubitemid 41686550)
38. Li,G, Fridman,R, Kim,HR. Tissue inhibitor of metalloproteinase-1 inhibits apoptosis of human breast epithelial cells. Cancer Res. 1999;59(24):6267-6275. (Pubitemid 30035652)
39. Davidsen ML, Wurtz SØ, Rømer MU, et al. TIMP-1 gene deficiency increases tumour cell sensitivity to chemotherapy-induced apoptosis. Br J Cancer. 2006;95(8):1114-1120.
40. Wurtz SO, Schrohl AS, Meijer-van Gelder ME, et al. High tumor tissue levels of tissue inhibitor of metalloproteinases-1 are associated with resistance to chemotherapy in patients with metastatic breast cancer. Proceedings of the 28th Annual San Antonio Breast Cancer Symposium. 2005; abstract no. 1033.
41. Sørensen NM, Byström P, Christensen IJ, et al. TIMP-1 is significantly associated with objective response and survival in metastatic colorectal cancer patients receiving combination of irinotecan, 5-fluorouracil, and folinic acid. Clin Cancer Res. 2007;13(14):4117-4122. (Pubitemid 47105974)
42. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK. WHO Classification of Tumours of the Central Nervous System. 4th ed. Lyon: International Agency for Research on Cancer; 2007.
43. Gundersen HJ. Stereology: the fast lane between neuroanatomy and brain function- or still only a tightrope? Acta Neurol Scand Suppl. 1992;137:8-13.
44. Madsen C, Schrøder HD. Ki-67 immunoreactivity in meningiomas-determination of the proliferative potential of meningiomas using the monoclonal antibody Ki-67. Clin Neuropathol. 1997;16(3):137-142. (Pubitemid 27244585)
45. Gilbertson RJ, Rich JN. Making a tumour's bed: glioblastoma stem cells and the vascular niche. Nat Rev Cancer. 2007;7(10):733-736.
46. Shibahara J, Kashima T, Kikuchi Y, Kunita A, Fukayama M. Podoplanin is expressed in subsets of tumors of the central nervous system. Virchows Arch. 2006;448(4):493-499.
47. Mishima K, Kato Y, Kaneko MK, Nishikawa R, Hirose T, Matsutani M. Increased expression of podoplanin in malignant astrocytic tumors as a novel molecular marker of malignant progression. Acta Neuropathol. 2006;111(5):483-488.
48. Nakamura Y, Kanemura Y, Yamada T, et al. D2-40 antibody immunoreactivity in developing human brain, brain tumors and cultured neural cells. Mod Pathol. 2006;19(7):974-985. (Pubitemid 43910477)
49. Dahlstrand J, Collins VP, Lendahl U. Expression of the class VI intermediate filament nestin in human central nervous system tumors. Cancer Res. 1992;52(19):5334-5341.
50. Tohyama T, Lee VM, Rorke LB, Marvin M, McKay RD, Trojanowski JQ. Nestin expression in embryonic human neuroepithelium and in human neuroepithelial tumor cells. Lab Invest. 1992;66(3):303-313.
51. Almqvist PM, Mah R, Lendahl U, Jacobsson B, Hendson G. Immunohistochemical detection of nestin in pediatric brain tumors. J Histochem Cytochem. 2002;50(2):147-158. (Pubitemid 34106754)
52. Ma YH, Mentlein R, Knerlich F, Kruse ML, Mehdorn HM, Held-Feindt J. Expression of stem cell markers in human astrocytomas of different WHO grades. J Neurooncol. 2008;86(1):31-45. (Pubitemid 350263430)
53. Bruggeman SW, Hulsman D, Tanger E, et al. Bmi1 controls tumor development in an Ink4a/Arf-independent manner in a mouse model for glioma. Cancer Cell. 2007;12(4):328-341. (Pubitemid 47539307)
54. Toth K, Vaughan MM, Peress NS, Slocum HK, Rustum YM. MDR1 P-glycoprotein is expressed by endothelial cells of newly formed capillaries in human gliomas but is not expressed in the neovasculature of other primary tumors. Am J Pathol. 1996;149(3):853-858. (Pubitemid 26334169)
55. Li L, Xie T. Stem cell niche: structure and function. Annu Rev Cell Dev Biol. 2005;21:605-631. (Pubitemid 41740648)
56. Liu W, Shen G, Shi Z, et al. Brain tumour stem cells and neural stem cells: still explored by the same approach? J Int Med Res. 2008;36(5):890-895.
57. Folkins C, Man S, Xu P, Shaked Y, Hicklin DJ, Kerbel RS. Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors. Cancer Res. 2007;67(8):3560-3564. (Pubitemid 46762138)
58. Salmaggi A, Boiardi A, Gelati M, et al. Glioblastoma-derived tumorospheres identify a population of tumor stem-like cells with angiogenic potential and enhanced multidrug resistance phenotype. Glia. 2006;54(8):850-860. (Pubitemid 44671990)
59. Engebraaten O, Bjerkvig R, Pedersen PH, Laerum OD. Effects of EGF, bFGF, NGF and PDGF(bb) on cell proliferative, migratory and invasive capacities of human brain-tumour biopsies in vitro. Int J Cancer. 1993;53(2):209-214. (Pubitemid 23042867)
60. Gensburger C, Labourdette G, Sensenbrenner M. Brain basic fibroblast growth factor stimulates the proliferation of rat neuronal precursor cells in vitro. FEBS Lett. 1987;217(1):1-5. (Pubitemid 17093537)
61. Reynolds BA, Tetzlaff W, Weiss S. A multipotent EGF-responsive striatal embryonic progenitor cell produces neurons and astrocytes. J Neurosci. 1992;12(11):4565-4574.
62. Reynolds BA, Weiss S. Clonal and population analyses demonstrate that an EGFresponsive mammalian embryonic CNS precursor is a stem cell. Dev Biol. 1996; 175(1):1-13. (Pubitemid 26150042)
63. Pontén J, Macintyre EH. Long term culture of normal and neoplastic human glia. Acta Pathol Microbiol Scand. 1968;74(4):465-486.
64. Yu SC, Ping YF, Yi L, et al. Isolation and characterization of cancer stem cells from a human glioblastoma cell line U87. Cancer Lett. 2008;265(1):124-134.
65. Wu A, Oh S, Wiesner SM, et al. Persistence of CD133(+) cells in human and mouse glioma cell lines: detailed characterization of GL261 glioma cells with cancer stem cell-like properties. Stem Cells Dev. 2008;17(1):173-184. (Pubitemid 351271617)
66. Yao XH, Ping YF, Chen JH, et al. Glioblastoma stem cells produce vascular endothelial growth factor by activation of a G-protein coupled formylpeptide receptor FPR. J Pathol. 2008;215(4):369-376.
67. Platet N, Liu SY, Atifi ME, et al. Influence of oxygen tension on CD133 phenotype in human glioma cell cultures. Cancer Lett. 2007;258(2):286-290. (Pubitemid 350110377)
68. Lázcoz P, Balbuena J, Enguita M, Fan X, Castresana JS. Expression of neural stem cell markers in glioblastoma, medulloblastoma and neuroblastoma cell lines. Proceedings of the 98th Annual Meeting of the American Association for Cancer Research. 2007; abstract no. 1280.
69. Strojnik T, Kavalar R, Lah TT. Experimental model and immunohistochemical analyses of U87 human glioblastoma cell xenografts in immunosuppressed rat brains. Anticancer Res. 2006;26(4B):2887-2900. (Pubitemid 44161777)
70. Aroca F, Renaud W, Bartoli C, Bouvier-Labit C, Figarella-Branger D. Expression of PECAM-1/CD31 isoforms in human brain gliomas. J Neurooncol. 1999;43(1):19-25. (Pubitemid 29351973)
71. Guedez L, Stetler-Stevenson WG, Wolff L, et al. In vitro suppression of programmed cell death of B cells by tissue inhibitor of metalloproteinases-1. J Clin Invest. 1998;102(11):2002-2010. (Pubitemid 29001847)
72. Lambert E, Boudot C, Kadri Z, et al. Tissue inhibitor of metalloproteinases-1 signalling pathway leading to erythroid cell survival. Biochem J. 2003;372(pt 3):767-774. (Pubitemid 36760390)
73. Liu XW, Bernardo MM, Fridman R, Kim HR. Tissue inhibitor of metalloproteinase-1 protects human breast epithelial cells against intrinsic apoptotic cell death via the focal adhesion kinase/phosphatidylinositol 3-kinase and MAPK signaling pathway. J Biol Chem. 2003;278(41):40364-40372. (Pubitemid 37248605)
74. Porter JF, Shen S, Denhardt DT. Tissue inhibitor of metalloproteinase-1 stimulates proliferation of human cancer cells by inhibiting a metalloproteinase. Br J Cancer. 2004;90(2):463-470. (Pubitemid 38250646)
75. Liu XW, Taube ME, Jung KK, et al. Tissue inhibitor of metalloproteinase-1 protects human breast epithelial cells from extrinsic cell death: a potential oncogenic activity of tissue inhibitor of metalloproteinase-1. Cancer Res. 2005;65(3):898-906.
76. Vogel TW, Zhuang Z, Li J, et al. Proteins and protein pattern differences between glioma cell lines and glioblastoma multiforme. Clin Cancer Res. 2005;11(10):3624-3632. (Pubitemid 40685577)
77. Bell HS, Whittle IR, Walker M, Leaver HA, Wharton SB. The development of necrosis and apoptosis in glioma: experimental findings using spheroid culture systems. Neuropathol Appl Neurobiol. 2001;27(4):291-304. (Pubitemid 32758617)
78. Sánchez-Beato M, Sánchez E, González-Carreró J, et al. Variability in the expression of polycomb proteins in different normal and tumoral tissues. A pilot study using tissue microarrays. Mod Pathol. 2006;19(5):684-694.
79. Kania G, Corbeil D, Fuchs J, et al. Somatic stem cell marker prominin-1/CD133 is expressed in embryonic stem cell-derived progenitors. Stem Cells. 2005;23(6):791-804. (Pubitemid 40791794)
80. Florek M, Haase M, Marzesco AM, et al. Prominin-1/CD133, a neural and hematopoietic stem cell marker, is expressed in adult human differentiated cells and certain types of kidney cancer. Cell Tissue Res. 2005;319(1):15-26. (Pubitemid 40104635)
81. Tóth K, Vaughan MM, Slocum HK, et al. New immunohistochemical "sandwich" staining method for mdr1 P-glycoprotein detection with JSB-1 monoclonal antibody in formalin-fixed, paraffin-embedded human tissues. Am J Pathol. 1994; 144(2):227-236. (Pubitemid 2041402)
82. Kahn HJ, Bailey D, Marks A. Monoclonal antibody D2-40, a new marker of lymphatic endothelium, reacts with Kaposi's sarcoma and a subset of angiosarcomas. Mod Pathol. 2002;15(4):434-440. (Pubitemid 34326952)
83. Ferri AL, Cavallaro M, Braida D, et al. Sox2 deficiency causes neurodegeneration and impaired neurogenesis in the adult mouse brain. Development. 2004;131(15):3805-3819. (Pubitemid 39199387)
84. Sorensen IV, Fenger C, Winther H, et al. Characterization of anti-TIMP-1 monoclonal antibodies for immunohistochemical localization in formalin-fixed, paraffin-embedded tissue. J Histochem Cytochem. 2006;54(10):1075-1086. (Pubitemid 44434711)